Red Flags Detected

  • Material Weakness (worsened) — Material weaknesses in internal controls persist since 2021; current filing cites acquisition-related accounting issues, though management claims 'small number' remain unremediated versus 'many' in prior year.
  • Going Concern (improved) — Going-concern language removed from MD&A (cash runway extended to year-end 2026 vs. mid-Q2 2025), but Risk Factors section retains substantial doubt disclosure with auditor flag.
NASDAQ: RNAZ Transcode Therapeutics, Inc. 10-K

TransCode acquires melanoma vaccine, raises $25M, completes Phase 1a; cash extends to year-end 2026

Filed April 15, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade RNAZ commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.